Latest news with #MankindPharma
Mint
a day ago
- Health
- Mint
India to introduce more advanced testing for imported blood products to reduce infection risk
New Delhi: The health ministry plans to mandate the use of a faster and more accurate method to test all imported blood products to maintain the highest safety standards and reduce the risk of infection from transfusions. The ministry intends to introduce nucleic acid testing (NAT) to improve the screening of imported blood products for antibodies of the human immunodeficiency virus (HIV), the hepatitis B virus, the hepatitis C virus and other impurities, an official aware of the matter said. The decision to shift to NAT has already been taken by the regulator, the Drug Controller General of India (DCGI), and the matter was discussed at the Drugs Technical Advisory Board meeting in April. The board is the highest statutory body responsible for advising the Central and state governments on technical matters related to the administration of the Drugs and Cosmetics Act, 1940. Also Read | Banking on blood: Health ministry frames guidelines to curb paid donations, improve efficacy of transfusions With the introduction of NAT, the conventional testing method known as ELISA, or enzyme-linked immunosorbent assay, will be done away with. ELISA, while a powerful tool, has several drawbacks, including the potential for false positive and negative results, apart from being time-consuming. The Department of Pharmaceuticals and the National Institute of Biologicals (NIB) in Noida had issued an alert in October after the NIB found three imported blood products—Berirab-P (used in rabies injections), Hepabig (to prevent hepatitis B virus infection) and Tetglob (used for tetanus treatment)—to be of sub-standard quality. When the Berirab-P and Hepabig samples were tested again at the National Institute of Virology in Pune using an advanced version of polymerase chain reaction, which is more sensitive than ELISA, they passed the test metrics. The set of Tetglob samples sent to a private laboratory that used ELISA were non-reactive. Safety standards Bharat Serums and Vaccines Ltd, now owned by Mankind Pharma, is the only company in the country that imports these lifesaving blood products. Imported blood products are used for the treatment of critically ill patients or those who are suffering thalassemia and other blood-related disorders. These products are tested at government laboratories to ensure they meet safety and quality standards. Also Read | India plans standard evaluation and quality protocols for HMPV' testing kits 'These are tested using conventional methods, but now the plan is to amend the rules to allow an advanced version of testing in line with international practices," the official said. 'NIB also proposed that an amendment may be considered to test blood products by NAT." Queries sent to the health ministry, the Department of Pharmaceuticals and the Mankind Pharma spokesperson remained unanswered till press time. 'NAT testing gives accurate and quick results and nowadays it is highly used. NAT testing is used for tuberculosis and NAT testing was modified during the covid-19 pandemic to detect the coronavirus," a scientist from the Indian Council of Medical Research said, requesting anonymity. 'The ELISA test may sometimes give false results if the viral load in the sample is low. However, PCR and NAT give accurate results even if the viral load is low." Also Read | ICMR and CDSCO develop framework for validation of pathogen identification and antimicrobial susceptibility testing According to an assessment by the National Blood Transfusion Council, the apex policymaking body for issues pertaining to blood and plasma, the clinical requirement of blood in the country is about 14.5 million units per year. The volume of each unit of blood is about 450 ml. In India, the import, manufacture, distribution and sale of drugs, cosmetics and notified medical devices are regulated by the Drugs and Cosmetics Act and the Drugs and Cosmetics Rules, 1945.
Mint
4 days ago
- Business
- Mint
Mankind to expand gastro, derma presence, says MD Rajeev Juneja
Mankind Pharma is focused on expanding its presence in the gastrointestinal and dermatology segments this year, as it looks at expanding its presence in the chronic segments, managing director Rajeev Juneja toldMintin an interview. 'We are not great in the gastro [segment]...we have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our inclination is towards the chronic side," Juneja said, adding thatgastro in India is one of the fastest-growing segments. 'Along with this, we are working on derma as well," he said. The gastro segment grew 7.3% year on year in April, according to pharma intelligence platform Pharmarack. Further, Mankind is developing a novel anti-obesity and diabetes drug in-house. The drug candidate, GRP119, is currently in phase 2 trials in Australia, and Juneja said that results are expected in the next six to nine months. In FY25, Mankind signed a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise its novel drug Vonoprazan, to treat Gastroesophageal Reflux Disease (GERD). Also Read: Sun Pharma to ramp up growth-boosting specialty portfolio in FY26 Juneja said that the company is evaluating all options to increase its presence in these therapy areas, including in-licensing products from innovators or small acquisitions. 'No past strategy can be guaranteed for future success. So we need to apply our mind and try to bring some kind of differentiation in whatever we do," said Juneja. 'The point is that once we decide that our intention is that we are supposed to be good on the gastro side, we start searching for avenues, we start searching for people, we start searching for products," he said. The company will also continue to strengthen its leadership in the women's health segment, which received a boost last year through its acquisition of Bharat Serum and Vaccines (BSV). With its foundation strengthened in FY25, Mankind aims to grow 1.2 to 1.3 times the Indian pharmaceutical market. Juneja said this will be driven by its focus on its chronic domestic formulations portfolio. Juneja said the focus is also on growing larger brands, from the current ₹50 crore to ₹100 crore brands for products to ₹500 crore brands. 'This is the strategy we basically want to pursue in future, because we have seen that once you create that kind of a brand, that's a very big entry barrier," he added. BSV acquisition Mankind is on track with the integration of BSV, which it acquired for ₹13,768 crore in October 2024. The integration will be funded through a mix of internal accruals and external debt. Juneja said the company focused on removing the 'extra flab" and bringing in the right talent for the acquired entity in FY25. This year, he expects 18-20% growth from the BSV portfolio. The goal is to increase the reach and awareness of BSV's niche super-speciality products. BSV is working on two biosimilars, the company's investor presentation highlighted, although Juneja declined to share more details on the BSV pipeline. Also Read: Emcure Pharmaceuticals to expand gynaecology, derma portfolio for India market in FY26 Vishal Manchanda, senior vice president of Institutional Equities at Systematix Group, toldMintthat BSV's platform and skillset for making recombinant drugs (created by inserting genes from one species into a host species) can be leveraged to make biosimilars. Select companies in India, including Biocon, are skilled at the recombinant process. However, Manchanda pointed out that Mankind has the potential to scale this up meaningfully. Innovation push 'If you're a pharma company, naturally, you gain respect once you have great R&D," Juneja said. 'We started our own R&D in Mankind 13-14 years back…going forward, we'll be putting a bit more money in the R&D side…our R&D expenses will increase because that would be the future need as well." 'We wish to become a bigger company…our dream is to become India's number one company on the domestic side," Juneja said, adding that 'we need to have certain innovative products, and we are working for that". Mankind's focus on innovation and speciality segments comes as the Indian pharmaceutical market has become more crowded. Most segments already have established market leaders. '…the promoters are realising that there is a challenge to growth. And they know the space they have been playing in is now kind of difficult to expand from where they are, meaningfully expand from where they are. So I think Mankind promoters being extremely committed to India business, they are also kind of prepared on how to take this forward," Manchanda said. 'What they are actually looking for is a bigger avenue to build growth on," he added, referring to Mankind's BSV acquisition. Internal corrections Mankind undertook several internal correction initiatives in the last year, including leadership changes and improving synergies between its divisions, Juneja said. Also Read: Zydus bets big on vaccines and medtech 'If you look at the history of Mankind, in 30 years, we have become the fourth largest company," Juneja said, adding that for any company growing very fast, there comes a time when growth plateaus. 'But once you bring commercial excellence, you bring people from outside…a number of flaws can come in front of you, and you have two choices: Either to remove those flaws gradually without affecting your sales and profit and growth, or second, do it immediately," Juneja said. 'We belong to the second category, and we decided that by March 2025, we'll clean up Mankind from every side," he added.
Business Standard
22-05-2025
- Business
- Business Standard
Mankind Pharma slides after Q4 PAT drops 11% YoY to Rs 421 cr
Mankind Pharma slipped 3.51% to Rs 2,444.25 after the company's consolidated net profit declined 10.71% to Rs 420.77 crore in Q4 FY25 as against Rs 471.24 crore posted in Q4 FY24. However, revenue from operations increased 27.19% year-on-year (YoY) to Rs 3,079.37 crore in the fourth quarter of FY25. Profit before tax from continuing operations was at Rs 515.43 crore in Q4 of FY25, registering a de-growth of 9.87% from Rs 571.91 crore reported in Q4 FY24. EBITDA grew 16.4% YoY to Rs 686 crore in the March 2025 quarter. EBITDA margin improved to 22.3% in Q4 FY25, compared to 24.3% recorded in the corresponding quarter previous year. Domestic revenue stood at Rs 2,544 crore in Q4 FY25, up by 18% YoY, while export revenue stood at Rs 535 crore, up by 100% YoY during the quarter. Export growth was driven by an increase in its base business supported by new launches in the last 12-24 months and consolidation of BSV. During the quarter, the company has launched 1 product in Q4 FY25 and 5 products in FY25, taking the total launched products to 44 in US. The companys consumer healthcare business reported a 14% increase in revenue to Rs 178 crore in Q4 FY25, supported by steady growth across all key brands. There was strong growth in secondary sales for Manforce Condoms, Gas-O-Fast, and HealthOK, with year-on-year increases of 17%, 29%, and 23%, respectively. The business also gained strong traction with the launches of Epic ThinX (unflavored premium category condom), Nimulid (pain management), and OvaNews (ovulation detection kit) in FY25. Rajeev Juneja, vice chairman & managing director, Mankind Pharma, said, Mankinds revenue grew by 27% with adjusted EBITDA margins at around 23% in Q4 FY25, led by continued 1.3x outperformance in chronic, strong growth in the consumer segment, and BSV consolidation. In FY25, reported revenue growth was 19% with an adj EBITDA margin of approximately 26%. This has been a transformative year at Mankind, with several strategic initiatives to ensure higher productivity and outperform IPM as seen in the past. BSV integration is progressing well with key focus on R&D, improving MR productivity & scaling mandate brands across domestic & international business. During FY25, weve laid a strong foundation to deliver long-term sustainable growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV. Meanwhile, the companys board has approved the incorporation of a wholly owned subsidiary, directly or indirectly, in Sri Lanka (Foreign WOS). Mankind Pharma is one of the largest pharmaceutical company in India, which focuses on the domestic market with its pan-India presence. Mankind Pharma operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Mankind Pharma shares slide 3% as Q4 profit declines; details here
Shares of Mankind Pharma dropped over 3 per cent on Thursday as the company reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25). The Delhi-based pharma major's stock fell as much as 3.22 per cent during the day to ₹2,450 per share, the biggest intraday fall since May 2 this year. The stock pared losses to trade 2.1 per cent lower at ₹2,478 apiece, compared to a 1 per cent decline in Nifty 50 as of 9:32 AM. Shares of the company extended losses to their fourth day and have fallen over 6 per cent from their recent highs of ₹2,610, which it hit earlier this month. The counter has fallen 14 per cent this year, compared to a 3.7 per cent advance in the benchmark Nifty 50. Mankind Pharma has a total market capitalisation of ₹1.01 trillion, according to BSE data. Mankind Pharma Q4FY25 results Mankind Pharma posted a 10 per cent fall in consolidated net profit Q4 FY25 at ₹424.65 crore from ₹476.59 crore in the same period last financial year. The pharma company's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. It added that this growth was partially supported by continued outperformance in the chronic segment, at 1.3 times the Indian pharma market. Mankind Pharma management commentary Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. About Mankind Pharma The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS vitamins /minerals/nutrients and respiratory.
Business Standard
22-05-2025
- Business
- Business Standard
Mankind Pharma consolidated net profit declines 10.71% in the March 2025 quarter
Sales rise 27.13% to Rs 3079.37 crore Net profit of Mankind Pharma declined 10.71% to Rs 420.77 crore in the quarter ended March 2025 as against Rs 471.24 crore during the previous quarter ended March 2024. Sales rose 27.13% to Rs 3079.37 crore in the quarter ended March 2025 as against Rs 2422.24 crore during the previous quarter ended March 2024. For the full year,net profit rose 4.08% to Rs 1990.96 crore in the year ended March 2025 as against Rs 1912.90 crore during the previous year ended March 2024. Sales rose 18.98% to Rs 12207.44 crore in the year ended March 2025 as against Rs 10260.44 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 3079.372422.24 27 12207.4410260.44 19 OPM % 22.1924.20 - 24.7224.50 - PBDT 746.30671.69 11 3137.552776.36 13 PBT 515.43571.91 -10 2516.332397.94 5 NP 420.77471.24 -11 1990.961912.90 4
